Humira
News/ News/ Sales and Marketing
AbbVie’s Humira tops ICER’s list of unwarranted price hikes again
Phil Taylor
AbbVie, Biogen, Humira, ICER, medicines spending, Novartis, pricing, Promacta, Tysabri, US
0 Comment
News/ News/ Sales and Marketing
FDA clears first “interchangeable” Humira biosimilar
Phil Taylor
AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval
0 Comment
Alvotech files lawsuit challenging AbbVie’s Humira patent thicket
Richard Staines
AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent
0 Comment
AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi
Richard Staines
AbbVie, Humira, inflammatory diseases, psoriatic arthritis, Skyrizi
0 Comment
News/ News/ Sales and Marketing
Despite biosims, ulcerative colitis drugs still cost too much; ICER
Phil Taylor
AbbVie, gastroenterology, Humira, inflammatory bowel disease, Johnson & Johnson, Merck & Co, Pfizer, Takeda, ulcerative colitis
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
3 key trends shaping the immunology market
George Underwood
AbbVie, biosimilars, Humira, immunology, interleukin inhibitors, J&J, Remicade, tnf inhibitors
0 Comment
Market Access/ News/ News/ News/ R&D/ Top stories
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis
Phil Taylor
AbbVie, Cosentyx, Eli Lilly, Humira, immunology, Novartis, psoriatic arthritis, Taltz
0 Comment